TrialSignal
Clinical trial intelligence report
A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01977573
Status
COMPLETED
Phase
Phase IIB
Sponsor
GlaxoSmithKline
Executive brief
Investment-Ready Snapshot
This study evaluated GSK1278863, a prolyl hydroxylase inhibitor, for safety and efficacy in treating anemia in non-dialysis dependent CKD patients. The trial involved 252 participants, with a focus on optimizing dosing for future Phase 3 trials.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01977573
Indication
Anaemia
Modality
small molecule
Target
Anemia associated with Chronic Kidney Disease (CKD)
Intervention
GSK1278863, rhEPO
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.